Immunosuppressants - Europe

Europe

In Europe, the Immunosuppressants market is anticipated to achieve a revenue of €6.19bn by 2024.
Looking ahead, it is projected to exhibit a Compound Annual Growth Rate (CAGR 2024-2029) of 15.37%, leading to a market volume of €12.65bn by 2029.
When compared globally, United States is expected to generate the highest revenue, with an estimated amount of €32,900.00m in 2024.
In Europe, Germany has seen a rising demand for immunosuppressants due to its high prevalence of autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for Immunosuppressants in Europe has been on the rise in recent years.

Customer preferences: The increasing prevalence of autoimmune diseases and organ transplantation has led to a rise in demand for Immunosuppressants in Europe. Patients suffering from autoimmune diseases require Immunosuppressants to reduce the activity of their immune system and prevent it from attacking healthy cells. Similarly, patients who undergo organ transplantation require Immunosuppressants to prevent their immune system from rejecting the transplanted organ.

Trends in the market: The Immunosuppressants market in Europe is expected to grow at a steady pace in the coming years. The market is expected to be driven by the increasing prevalence of autoimmune diseases and organ transplantation, as well as the growing geriatric population. In addition, the introduction of new and innovative Immunosuppressants is expected to further boost the growth of the market.Germany is the largest market for Immunosuppressants in Europe, followed by the United Kingdom and France. These countries are expected to continue to dominate the market in the coming years. However, other countries such as Spain and Italy are also expected to witness significant growth in the market.

Local special circumstances: The Immunosuppressants market in Europe is highly regulated. The European Medicines Agency (EMA) regulates the approval and marketing of Immunosuppressants in the European Union. In addition, each country has its own regulatory authority that oversees the approval and marketing of Immunosuppressants.

Underlying macroeconomic factors: The Immunosuppressants market in Europe is expected to be driven by the growing geriatric population and increasing prevalence of autoimmune diseases and organ transplantation. In addition, the introduction of new and innovative Immunosuppressants is expected to further boost the growth of the market. However, the market is also expected to face challenges such as high cost of treatment and regulatory hurdles.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.